(Q40409972)

20 September 2017

Virus-like particle vaccine by intranasal vaccination elicits protective immunity against respiratory syncytial viral infection in mice (English)

1 reference

20 September 2017

16

1 reference

20 September 2017

Mengying Cai

1

1 reference

20 September 2017

Cheng Wang

2

1 reference

20 September 2017

Yufeng Li

3

1 reference

20 September 2017

Hongjing Gu

4

1 reference

20 September 2017

Sujing Sun

5

1 reference

20 September 2017

Yueqiang Duan

6

1 reference

20 September 2017

Chengcai Lai

7

1 reference

20 September 2017

Keyu Wang

8

1 reference

20 September 2017

Xiaolan Yang

9

1 reference

20 September 2017

Li Xing

10

1 reference

20 September 2017

Peirui Zhang

11

1 reference

20 September 2017

Zhaohai Wang

12

1 reference

20 September 2017

Shaogeng Zhang

13

1 reference

20 September 2017

Xiaodong Guo

14

1 reference

20 September 2017

Shubing Liu

15

1 reference

20 September 2017

Xiliang Wang

17

1 reference

20 September 2017

Penghui Yang

18

1 reference

20 September 2017

14 December 2016

1 reference

Acta Biochimica et Biophysica Sinica

20 September 2017

1 reference

20 September 2017

49

1 reference

20 September 2017

1

1 reference

20 September 2017

74-82

1 reference

Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis

20 September 2017

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMW118

Immunity to and frequency of reinfection with respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMW118

Immunogenicity and efficacy of recombinant RSV-F vaccine in a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMW118

Viral and host factors in human respiratory syncytial virus pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMW118

Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMW118

Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMW118

Recombinant Sendai virus expressing the G glycoprotein of respiratory syncytial virus (RSV) elicits immune protection against RSV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMW118

Single intranasal immunization with recombinant adenovirus-based vaccine induces protective immunity against respiratory syncytial virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMW118

Long-term and memory immune responses in mice against Newcastle disease virus-like particles containing respiratory syncytial virus glycoprotein ectodomains

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMW118

Protection conferred by virus-like particle vaccines against respiratory syncytial virus infection in mice by intranasal vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMW118

Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMW118

Virus-like nanoparticle and DNA vaccination confers protection against respiratory syncytial virus by modulating innate and adaptive immune cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMW118

Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMW118

Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMW118

Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMW118

Additive protection induced by mixed virus-like particles presenting respiratory syncytial virus fusion or attachment glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMW118

Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMW118

Synthesis of rotavirus-like particles in insect cells: comparative and quantitative analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMW118

Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMW118

Immunomodulatory drugs and therapeutic vaccine in chronic hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMW118

Enhanced proliferative effects of a baculovirus-produced fusion protein of insulin-like growth factor and alpha(1)-proteinase inhibitor and improved anti-elastase activity of the inhibitor with glutamate at position 351.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMW118

Influence of baculovirus-host cell interactions on complex N-linked glycosylation of a recombinant human protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMW118

CpG containing oligodeoxynucleotides are potent adjuvants for parenteral vaccination with the fusion (F) protein of respiratory syncytial virus (RSV).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMW118

Humoral, mucosal, and cellular immune response to topical immunization with a subunit respiratory syncytial virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMW118

Mucosal immunity and nasal influenza vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMW118

Safety and immunogenicity of a live attenuated RSV vaccine in healthy RSV-seronegative children 5 to 24 months of age

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FABBS%2FGMW118

https://api.fatcat.wiki/v0/release/dzcbwcqk5nht5jazqg4cesppv4

21 January 2018

Identifiers

1 reference

mapped directly with Wikidata item

30 July 2022

based on heuristic

Fatcat ID

release_dzcbwcqk5nht5jazqg4cesppv4

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/dzcbwcqk5nht5jazqg4cesppv4

mapped directly with Wikidata item

30 July 2022

based on heuristic

1 reference

https://api.fatcat.wiki/v0/release/dzcbwcqk5nht5jazqg4cesppv4